SI3694505T1 - Spojina in sestavek za uporabo pri preventivnem in/ali kurativnem zdravljenju bolezni centralnega živčnega sistema, za katere je značilno zmanjšanje nevronske plastičnosti, zlasti značilno za zmanjšanje sinaptične plastičnosti - Google Patents
Spojina in sestavek za uporabo pri preventivnem in/ali kurativnem zdravljenju bolezni centralnega živčnega sistema, za katere je značilno zmanjšanje nevronske plastičnosti, zlasti značilno za zmanjšanje sinaptične plastičnostiInfo
- Publication number
- SI3694505T1 SI3694505T1 SI201831020T SI201831020T SI3694505T1 SI 3694505 T1 SI3694505 T1 SI 3694505T1 SI 201831020 T SI201831020 T SI 201831020T SI 201831020 T SI201831020 T SI 201831020T SI 3694505 T1 SI3694505 T1 SI 3694505T1
- Authority
- SI
- Slovenia
- Prior art keywords
- decline
- plasticity
- preventive
- diseases
- compound
- Prior art date
Links
- 230000007423 decrease Effects 0.000 title 2
- 210000003169 central nervous system Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000009109 curative therapy Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000007996 neuronal plasticity Effects 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 230000003956 synaptic plasticity Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE2017/5731A BE1025644B1 (fr) | 2017-10-13 | 2017-10-13 | Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale |
| PCT/EP2018/076133 WO2019072568A1 (fr) | 2017-10-13 | 2018-09-26 | Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique |
| EP18773776.2A EP3694505B1 (fr) | 2017-10-13 | 2018-09-26 | Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3694505T1 true SI3694505T1 (sl) | 2024-02-29 |
Family
ID=60164541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201831020T SI3694505T1 (sl) | 2017-10-13 | 2018-09-26 | Spojina in sestavek za uporabo pri preventivnem in/ali kurativnem zdravljenju bolezni centralnega živčnega sistema, za katere je značilno zmanjšanje nevronske plastičnosti, zlasti značilno za zmanjšanje sinaptične plastičnosti |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200237812A1 (sl) |
| EP (1) | EP3694505B1 (sl) |
| CN (1) | CN111315373A (sl) |
| BE (1) | BE1025644B1 (sl) |
| BR (1) | BR112020007341A2 (sl) |
| CA (1) | CA3079410A1 (sl) |
| DK (1) | DK3694505T3 (sl) |
| ES (1) | ES2965493T3 (sl) |
| FI (1) | FI3694505T3 (sl) |
| MX (1) | MX2020003844A (sl) |
| PL (1) | PL3694505T3 (sl) |
| PT (1) | PT3694505T (sl) |
| SI (1) | SI3694505T1 (sl) |
| WO (1) | WO2019072568A1 (sl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020229443A1 (fr) * | 2019-05-16 | 2020-11-19 | Synapharm Industrial Synthesis | Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel |
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
| IT1237435B (it) | 1989-12-14 | 1993-06-04 | Farmaco attivo nel ripristino della plasticita' neuronale. | |
| FR2704391B1 (fr) * | 1993-04-27 | 1995-06-02 | Boiron | Complément nutritionnel absorbable pour faciliter l'adaptation au stress quodidien. |
| US7148192B2 (en) * | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
| EP1981522B1 (en) | 2006-01-23 | 2012-09-12 | President and Fellows of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| US8178133B2 (en) * | 2007-03-22 | 2012-05-15 | Magceutics, Inc. | Magnesium compositions and uses thereof |
| JP2010522216A (ja) * | 2007-03-22 | 2010-07-01 | リュー，グオソン | マグネシウム組成物およびその使用 |
| US20110072525A1 (en) * | 2009-09-22 | 2011-03-24 | Effat Emamian | Compositions and methods for the treatment of psychiatric and neurological disorders |
| JP2013506678A (ja) * | 2009-09-30 | 2013-02-28 | クレイトン ビーリー，ハーラン | 体重を維持した禁煙および栄養補助剤 |
| FI129157B (fi) * | 2012-05-28 | 2021-08-13 | Biohit Oyj | Koostumus käytettäväksi vakavien päänsärkyjen esiintymistiheyden pienentämiseksi tai niiden vähentämiseksi |
| BR112015023215A2 (pt) * | 2013-03-15 | 2017-07-18 | Buck Inst Res Aging | suplementos cognitivos aprimorados |
| EA201790017A1 (ru) * | 2014-06-24 | 2017-06-30 | Дедраф Холдинг Б.В. | Новая минеральная композиция |
-
2017
- 2017-10-13 BE BE2017/5731A patent/BE1025644B1/fr active IP Right Grant
-
2018
- 2018-09-26 PL PL18773776.2T patent/PL3694505T3/pl unknown
- 2018-09-26 US US16/754,994 patent/US20200237812A1/en not_active Abandoned
- 2018-09-26 BR BR112020007341-5A patent/BR112020007341A2/pt unknown
- 2018-09-26 CA CA3079410A patent/CA3079410A1/en active Pending
- 2018-09-26 CN CN201880072217.XA patent/CN111315373A/zh active Pending
- 2018-09-26 SI SI201831020T patent/SI3694505T1/sl unknown
- 2018-09-26 DK DK18773776.2T patent/DK3694505T3/da active
- 2018-09-26 FI FIEP18773776.2T patent/FI3694505T3/fi active
- 2018-09-26 PT PT187737762T patent/PT3694505T/pt unknown
- 2018-09-26 WO PCT/EP2018/076133 patent/WO2019072568A1/fr unknown
- 2018-09-26 EP EP18773776.2A patent/EP3694505B1/fr active Active
- 2018-09-26 MX MX2020003844A patent/MX2020003844A/es unknown
- 2018-09-26 ES ES18773776T patent/ES2965493T3/es active Active
-
2021
- 2021-09-22 US US17/482,003 patent/US20220008455A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BE1025644A1 (fr) | 2019-05-10 |
| BE1025644B1 (fr) | 2019-05-15 |
| CN111315373A (zh) | 2020-06-19 |
| BR112020007341A2 (pt) | 2020-10-06 |
| US20220008455A1 (en) | 2022-01-13 |
| EP3694505B1 (fr) | 2023-10-04 |
| PL3694505T3 (pl) | 2024-04-02 |
| CA3079410A1 (en) | 2019-04-18 |
| US20200237812A1 (en) | 2020-07-30 |
| ES2965493T3 (es) | 2024-04-15 |
| PT3694505T (pt) | 2023-12-05 |
| DK3694505T3 (da) | 2024-01-02 |
| FI3694505T3 (fi) | 2023-12-20 |
| MX2020003844A (es) | 2020-11-06 |
| EP3694505A1 (fr) | 2020-08-19 |
| WO2019072568A1 (fr) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3407889T1 (sl) | Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema | |
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| IL246579B (en) | Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| PT3377637T (pt) | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele | |
| WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| WO2015197193A3 (en) | New use for jnk inhibitor molecules for treatment of various diseases | |
| MX2021003905A (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| ZA201900519B (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| EP3689875A4 (en) | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND COMPOSITIONS THEREOF, FOR THE TREATMENT OF PRC2-MEDIATED DISEASES | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
| EP3185862A4 (en) | PROTECTIVE METALOTHION ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES | |
| GB2561747B (en) | Composition for treating motor neuron diseases and use thereof | |
| IL277238A (en) | Modified oligonucleotides for use in the treatment of tauopathy | |
| PT3694505T (pt) | Composto e composição para utilização no tratamento preventivo e/ou curativo de doenças do sistema nervoso central caracterizadas por um diminuição da elasticidade neuronal, caracterizado particularmente por uma diminuição da elasticidade sináptica | |
| EP3831821A4 (en) | COMPOUND FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND ITS USE | |
| EP4043012A4 (en) | MEDICINAL PRODUCTS FOR TREATING ARTERY DISEASES AND USE THEREOF | |
| ZA201905309B (en) | Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals | |
| KR102316727B9 (ko) | 아토피성 질환 예방 또는 치료용 약학적 조성물 | |
| IL265976A (en) | Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions | |
| PH12018502568A1 (en) | Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections | |
| PT3408373T (pt) | Estirpe bacteriana como agente para evitar e/ou tratar distúrbios respiratórios | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. |